RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
化疗对肺癌患者循环淋巴细胞亚群的影响
英文原题：Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients.
查看英文原题
Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
化疗以治疗特异性的方式显著影响淋巴细胞亚群。
中文摘要
目的
肺癌仍是癌症相关死亡的主要原因，化疗是治疗的重要组成部分。化疗诱导的骨髓抑制涉及多种血液学指标下降，不仅包括中性粒细胞，也包括淋巴细胞、血红蛋白和血小板。本回顾性队列研究考察外周血淋巴细胞亚群的变化，旨在据此完善患者管理策略，在最大化化疗获益的同时减少其有害影响。
患者与方法
回顾性分析159例肺癌患者。患者分为“NT”组（n=108，既往未接受抗肿瘤治疗）和“PT”组（n=51，既往接受治疗后至少停治2个月）。化疗后重新评估患者，并分为“早期周期”组（接受不超过4个周期）和“后期周期”组（接受超过4个周期）。
结果
分析各组T细胞（CD4阳性、CD8阳性）、B细胞及自然杀伤（NK）细胞亚群比例。T细胞方面，早期周期组显著高于NT组（0.7783比0.7271；P=0.0017）及PT组（0.7783比0.6804；P=1.6×10⁻⁵）。B细胞从NT组至后期周期组（0.1014比0.0817；P=2.2×10⁻⁵）和PT组至后期周期组（0.1317比0.0817；P=6.2×10⁻¹⁰）均显著下降。早期周期组NK细胞显著低于NT组（0.1109比0.1462；P=0.00816）和PT组（0.1109比0.1513；P=0.00992）；后期周期组与NT或PT组相比均无显著变化（P>0.05）。
结论
化疗以治疗阶段相关的方式显著影响淋巴细胞亚群。早期周期组NK细胞减少而T细胞增加，提示先天免疫受损并早期转向适应性免疫；后期周期组B细胞显著下降，表明体液免疫成分受到延迟影响。
展开英文摘要原文
PURPOSE
Lung cancer remains a leading cause of cancer-related death and chemotherapy stands as a fundamental component in therapy. Chemotherapy-induced myelosuppression encompasses a spectrum of hematological declines, including not only neutrophils but also lymphocytes, hemoglobin levels and platelets. This retrospective cohort study investigates alterations in peripheral blood lymphocyte subsets. By uncovering these changes, our goal is to refine patient management strategies, ensuring that the benefits of chemotherapy are maximized while minimizing its detrimental effects.
PATIENTS AND METHODS
We retrospectively analyzed 159 lung cancer patients. Patients were categorized as "NT" (n=108, no previous anti-tumor therapy), and "PT" (n=51, prior therapy followed by at least a two-month treatment-free interval). Post-chemotherapy, patients were reassessed and grouped into "EarlyCycle" for those who underwent four or fewer cycles, and "LateCycle" for those who underwent more than four cycles.
RESULTS
The study focused on analyzing the percentages of lymphocyte subsets, including T cells (CD4+, CD8+), B cells, and natural killer (NK) cells, across these groups. For T cells, the EarlyCycle group exhibited a significant increase compared to NT (0.7783 vs 0.7271; p=0.0017) and PT (0.7783 vs 0.6804; p=1.6e-05). B cells showed a significant decrease from NT to LateCycle (0.1014 vs 0.0817; p=2.2e-05) and from PT to LateCycle (0.1317 vs 0.0817; p=6.2e-10). NK cells significantly decreased in the EarlyCycle group compared to NT (0.1109 vs 0.1462; p=0.00816) and PT (0.1109 vs 0.1513; p=0.00992), with no significant change in the LateCycle group compared to either NT or PT (p>0.05).
CONCLUSION
Chemotherapy significantly affects lymphocyte subsets in a treatment-specific manner. The EarlyCycle group experienced a reduction in NK cell and an increase in T cell, suggesting a damage of innate immunity and an early shift towards adaptive immunity. The LateCycle group showed a substantial decrease in B cell, indicating a delayed effect on humoral immunity components.
论文信息
- 作者
- Hong W、Zhang L、Qi Y、Wang Y、Wang W
- 第一作者单位
- Oncology, The Second People's Hospital of Liaocheng, Liaocheng, Shandong, People's Republic of China.China
- 通讯作者单位
- Critical Care Medicine, The Second People's Hospital of Liaocheng, Liaocheng, Shandong, People's Republic of China.China
- 期刊
- Cancer management and research2024
- 原文标识
- PubMed 39282611 · DOI 10.2147/CMAR.S475967
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →